Sign In
Buy MRNA
$47.44
-4.15 (-8.04%)
At Close: Jun 05, 2026
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
09:57am, Tuesday, 11'th Apr 2023
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Moderna Stock Skids Below Key Line On Unexpected Flu Shot Debacle
09:54am, Tuesday, 11'th Apr 2023
Moderna stock skidded Tuesday on a mixed update for its mRNA-based flu vaccine. The update could impact the shot's commercial timing.
Vaccines For Lyme Disease And Norovirus? Moderna Working On Shots Targeting Tick-Borne Infection And Vomiting Bug
09:52am, Tuesday, 11'th Apr 2023
Lyme is Moderna's first attempt at creating a vaccine for a bacterial infection.
Moderna Stock Slides Despite Positive Vaccines Update. Here's Why.
08:57am, Tuesday, 11'th Apr 2023
The biotech company is working on new drugs for Lyme disease and Covid-19 as it prepares to roll out six new products with “sizable markets.”
Moderna says it expects up to $15 billion in sales of Covid, RSV, flu vaccines in 2027
08:54am, Tuesday, 11'th Apr 2023
Moderna said it sees a corresponding operating profit from its Covid, RSV, and flu vaccines in the range of $4 billion to $9 billion in 2027.
Moderna is developing a vaccine candidate against Lyme disease that would be its first bacterial vaccine
07:27am, Tuesday, 11'th Apr 2023
Moderna Inc. MRNA, +1.19% outlined its clinical goals for its mRNA platform on Tuesday to mark its 4th Vaccine Day, including a new development candidate against Lyme disease that would be its first b
3 Overvalued Blue-Chip Stocks Not Worth Your Green
06:45am, Tuesday, 11'th Apr 2023
This year, stock markets have experienced growth, although not uniformly. Some stocks are recovering, while others are still declining or stagnating.
Moderna expects to have cancer and heart disease vaccines ready by the end of the decade
03:27am, Tuesday, 11'th Apr 2023
Moderna Therapeutics Inc is aiming to develop life-saving vaccines for cancer, heart disease, and other conditions by 2030, according to remarks made by the company's chief medical officer, Dr Paul
Moderna says it hopes to offer new vaccines for cancer, heart disease, and other conditions by 2030
03:28pm, Monday, 10'th Apr 2023
Moderna's chief medical officer said advancements in mRNA technology since the outset of the Covid pandemic have ushered in a golden age for new vaccines.
Moderna (MRNA), Merck's Cancer Jab Gets EMA's PRIME Tag
12:56pm, Monday, 10'th Apr 2023
The EMA grants PRIME designation to Moderna's (MRNA) personalized cancer vaccine candidate combined with Merck's Keytruda for treating certain types of melanoma.
Moderna Surges On A Key Win For Its Merck-Partnered Cancer Vaccine In Europe
10:01am, Monday, 10'th Apr 2023
Moderna stock inched ahead Monday after European regulators granted its Merck-partnered personalized cancer vaccine a key designation. The post Moderna Surges On A Key Win For Its Merck-Partnered Canc
Inflation Data, Disney Layoffs, Moderna's Prospects, and More Market News
07:30am, Saturday, 08'th Apr 2023
Plus Brad Stone, head of Bloomberg's global tech coverage, shares insights about Amazon and what to watch in the growing AI industry.
5 S&P 500 Stocks Showing Strength As Recession Fears Rise
01:14pm, Friday, 07'th Apr 2023
Medical stocks are holding up amid economic and market uncertainty. The post 5 S&P 500 Stocks Showing Strength As Recession Fears Rise appeared first on Investor's Business Daily.
5 Top Growth Stocks to Buy Before the Next Bull Market
05:30am, Thursday, 06'th Apr 2023
When the market is in the doldrums, it's time to go bargain hunting. Many top growth stocks have suffered in recent times -- and some have what it takes to soar when the general environment improves.
Could This Move by Johnson & Johnson Equal Billions for Moderna?
05:30am, Sunday, 02'nd Apr 2023
J&J is dropping out of the adult RSV vaccine race. This leaves the market to Moderna, Pfizer, and GSK; all three are close to reaching commercialization with their vaccine candidates.
